NCT05823987View on ClinicalTrials.gov

Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 16, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

H101

a modified human recombinant type 5 adenovirus with genetic modifications

DRUG

Tislelizumab

a PD-1 immune check inhibitor

DRUG

Lenvatinib

Lenvatinib capsules

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER